Table 2 Treatment outcomes stratified by treatment group and day of follow-up

Day 14

Clinical failure

ETF

14/309

(4.5)

[2.6–7.3]

4/368

(1.1)

[0.3–2.6]

2/372

(0.5)

[0.1–1.7]

0/335

(0)

LCF

29/309

(9.4)

[6.5–13.0]

2/368

(0.5)

[0.1–1.7]

0/372

(0)

0/335

(0)

Parasitological failure

LPF

56/309

(18.1)

[14.1–22.7]

3/368

(0.8)

[0.2–2.2]

0/372

(0)

0/335

(0)

Overall Treatment failure

99/309

(32.0)

[27.0–37.4]

9/368

(2.4)

[1.2–4.4]

2/372

(0.5)

[0.1–1.7]

0/335

(0)

Day 28 Unadjusted by genotyping

Clinical failure

ETF

14/300

(4.7)

[2.7–7.5]

4/361

(1.1)

[0.4–2.7]

2/356

(0.6)

[0.1–1.8]

0/330

(0)

LCF

45/300

(15.0)

[11.3–19.4]

4/361

(1.1)

[0.4–2.7]

3/356

(0.8)

[0.2–2.3]

4/330

(1.2)

[0.4–2.9]

Parasitological failure

LPF

104/300

(34.7)

[29.4–40.2]

8/361

(2.2)

[1.0–4.2]

6/356

(1.7)

[0.7–3.5]

8/330

(2.4)

[1.1–4.6]

Overall Treatment failure

163/300

(54.4)

[48.7–59.9]

16/361

(4.4)

[2.6–6.9]

11/356

(3.1)

[1.6–5.3]

12/330

(3.6)

[2.0–6.1]

Day 28 Adjusted by genotyping

Clinical failure

ETF

14/300

(4.7)

[2.7–7.5]

4/361

(1.1)

[0.4–2.7]

2/356

(0.6)

[0.1–1.8]

0/330

0

[0.4–2.7]

LCF

34/300

(11.3)

[8.1–15.3]

3/361

(0.8)

[0.2–2.2]

1/356

(0.3)

[0–1.4]

2/330

(0.6)

[0.1–2.0]

Parasitological failure

LPF

84/300

(28.0)

[23.1–33.3]

5/361

(1.4)

[0.5–3.0]

3/356

(0.8)

[0.2–2.3]

4/330

(1.2)

[0.4–2.9]

Overall Treatment failure

132/300

(44.0)

[38.5–49.7]

12/361

(3.3)

[1.8–5.6]

6/356

(1.7)

[0.7–3.5]

6/330

(1.8)

[0.7–3.7]